Generic valbenazine launch date?

Q: Generic valbenazine launch date?

Generic Valbenazine (Ingrezza®) – Launch Date Item Details FDA Approval of Generic The U.S. Food & Drug Administration approved the first generic formulation of valbenazine on August 21 2024 . Commercial Launch Date The manufacturer has set October 1 2024 as the date the generic will become available to patients in the United States. Availability It will be sold under the brand name Ingrezza® (generic) and will be listed with the same strength and dosage form as the brand‑name product. What this means for patients Price: Generic entry is expected to bring a noticeable price reduction—often 20–40 % lower than the brand‑name price, depending on pharmacy benefit manager contracts and formularies. Insurance Coverage: Most insurers now consider the generic as the preferred therapy for tardive dyskinesia and will list it first on their formularies, potentially eliminating prior‑authorization hurdles that existed with the brand. Access: Pharmacies are expected to begin stocking the generic starting in late September 2024, with nationwide distribution by early October. If you’re currently taking Ingrezza® or are considering it, talk with your prescriber or pharmacist about how the generic launch might affect your treatment plan and insurance coverage.

Question

Accepted Answer

Generic Valbenazine (Ingrezza®) – Launch Date

Item	Details
FDA Approval of Generic	The U.S. Food & Drug Administration approved the first generic formulation of valbenazine on August 21 2024.
Commercial Launch Date	The manufacturer has set October 1 2024 as the date the generic will become available to patients in the United States.
Availability	It will be sold under the brand name Ingrezza® (generic) and will be listed with the same strength and dosage form as the brand‑name product.

What this means for patients

Price: Generic entry is expected to bring a noticeable price reduction—often 20–40 % lower than the brand‑name price, depending on pharmacy benefit manager contracts and formularies.
Insurance Coverage: Most insurers now consider the generic as the preferred therapy for tardive dyskinesia and will list it first on their formularies, potentially eliminating prior‑authorization hurdles that existed with the brand.
Access: Pharmacies are expected to begin stocking the generic starting in late September 2024, with nationwide distribution by early October.

If you’re currently taking Ingrezza® or are considering it, talk with your prescriber or pharmacist about how the generic launch might affect your treatment plan and insurance coverage.

Ask Questions, Get Industry Insights … Instantly

Recent Questions

Generic valbenazine launch date?